Demonstrating the value for money of implementing evidence-based treatment: the case for further investment in magnesium sulphate as a neuroprotectant for preterm births
The case of MgSO<sub>4</sub> treatment for preterm birth illustrates how sub-optimal implementation of evidence-based interventions can be associated with high opportunity costs measured as INMB forgone. This approach provides valuable quantification of the value for money of future QI programmes to improve the implementation of these interventions.
Authors
- Carlos Sillero‐Rejon (ORCID: https://orcid.org/0000-0001-5502-9247)
- K LUYT
- Hannah B Edwards (ORCID: https://orcid.org/0000-0002-1885-4771)
- David Odd (ORCID: https://orcid.org/0000-0002-6416-4966)
- Sabi Redwood (ORCID: https://orcid.org/0000-0002-2159-1482)
- Hugh McLeod (ORCID: https://orcid.org/0000-0002-2266-7303)
- Frank de Vocht
- Christalla Pithara-McKeown
- William Hollingworth
- Brent C. Opmeer
Institutions
- Cardiff and Vale University Health Board (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- University of Bristol (GB)
- Dutch Expert Centre for Screening (NL)
- St Michael's Hospital (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Frontiers in Health Services
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/frhs.2025.1655385
- Primary Topic
- Preterm Birth and Chorioamnionitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University Hospitals Bristol NHS Foundation Trust
- National Institute for Health and Care Research
- Department of Health and Social Care
- Oxford Academic Health Science Network
- National Institute for Health Research Applied Research Collaboration West